


What is claimed is:

1. A protease inhibitor represented by the following structure:



wherein

R₁ is selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;

R₂ is selected from the group consisting of -CH₂-Phenyl, and -CH₂-CH(CH₃)₂;

R₃ is selected from the group consisting of hydrogen, oxygen and hydroxyl; R₄ is selected from the group consisting of hydrogen, oxygen and hydroxyl, wherein R₃ and R₄ are not both hydroxyl and wherein R₃ and R₄ are either a single combined oxygen forming a carbonyl group;


R₅ is selected from the group consisting of hydrogen, and oxygen; R₆ is selected from the group consisting of hydrogen, and oxygen, wherein R₅ and R₆ are either a single combined oxygen forming a carbonyl group or both separately hydrogen;

BEST AVAILABLE COPY

09581044-060800


-70-

R_7 is a radical represented by the formula:



wherein R_8 is a radical selected from the group consisting of $(H)_2$, and $-H(t\text{-Butyl})$.

2. A protease inhibitor represented by the following structure:




wherein R_1 is a radical selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; R_2 is selected from the group consisting of $-CH_2\text{-Phenyl}$, and $-CH_2\text{-CH(CH}_3)_2$; R_3 is a radical selected from the group consisting of hydrogen, and $-OH$.

BEST AVAILABLE COPY

-71-

3. A protease inhibitor represented by the following structure:




wherein

R₁ is a radical selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; and

R₂ is a radical selected from the group consisting of - (H)₂, and -H(t-Butyl).

4. A protease inhibitor represented by the following structure:



BEST AVAILABLE COPY

509581044060800

15


20

-72-

BEST AVAILABLE COPY

wherein R_1 is a radical selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-valine-valine- and carbobenzyloxy-alanine-asparagine-.

5. A protease inhibitor represented by the following structure:



wherein R_1 is a radical selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-valine-valine- and carbobenzyloxy-alanine-asparagine-.

ADD
A2
add CS

09531044-050300